Arcus Biosciences’ (RCUS) Buy Rating Reaffirmed at Mizuho

Arcus Biosciences (NYSE:RCUS – Get Rating)‘s stock had its “buy” rating reissued by equities researchers at Mizuho in a research report issued on Friday, Benzinga reports. They currently have a $51.00 target price on the stock. Mizuho’s price target would indicate a potential upside of 210.03% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Barclays decreased their price target on shares of Arcus Biosciences from $60.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, December 21st. Citigroup decreased their price target on shares of Arcus Biosciences from $42.00 to $40.00 in a research note on Thursday, March 9th. TheStreet downgraded shares of Arcus Biosciences from a “c-” rating to a “d” rating in a research note on Tuesday, February 28th. Finally, Bank of America started coverage on shares of Arcus Biosciences in a research note on Friday, November 18th. They issued a “neutral” rating and a $33.00 price target for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Arcus Biosciences Stock Down 3.0 %

Shares of NYSE RCUS opened at $16.45 on Friday. Arcus Biosciences has a twelve month low of $15.70 and a twelve month high of $39.75. The firm has a fifty day simple moving average of $19.52 and a 200 day simple moving average of $24.06. The company has a market capitalization of $1.20 billion, a PE ratio of -4.42 and a beta of 0.89.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Arizona State Retirement System grew its holdings in shares of Arcus Biosciences by 4.5% during the fourth quarter. Arizona State Retirement System now owns 12,217 shares of the company’s stock valued at $253,000 after buying an additional 523 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Arcus Biosciences by 2.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,094 shares of the company’s stock worth $457,000 after purchasing an additional 551 shares during the last quarter. HM Payson & Co. boosted its holdings in Arcus Biosciences by 70.0% during the third quarter. HM Payson & Co. now owns 1,700 shares of the company’s stock worth $44,000 after purchasing an additional 700 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in Arcus Biosciences by 2.0% during the third quarter. State of Alaska Department of Revenue now owns 35,970 shares of the company’s stock worth $940,000 after purchasing an additional 710 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its holdings in Arcus Biosciences by 1.0% during the fourth quarter. New York State Teachers Retirement System now owns 83,751 shares of the company’s stock worth $1,732,000 after purchasing an additional 800 shares during the last quarter. 72.97% of the stock is currently owned by institutional investors and hedge funds.

About Arcus Biosciences

(Get Rating)

Arcus Biosciences, Inc engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.